Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib vs Salvage Chemotherapy in Relapsed or Refractory FLT3-Mutated AML
NCT03182244Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2017
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of gilteritinib in acute myeloid leukemia (AML) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Overall Survival. Started Oct 2017; status: completed.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03182244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03182244.